Is axsm a buy?
The Axsome Therapeutics stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock.
What is the price of target stock?
The price target of a stock is the price at which the stock is fairly valued with respect to its historical and projected earnings. When stocks are trading below and above their price targets, investors can maximize their rates of return by buying and selling. Stock price targets are often published by research analysts.
What is target stock price?
The stock has a market cap of $20.58 billion, a price-to-earnings ratio of 875.81, a PEG ratio of 2.71 and a beta of 1.25. ZoomInfo Technologies has a fifty-two week low of $37.86 and a fifty-two week high of $79.17.
What is target share price?
Three of SPXV's underlying holdings with notable upside to their analyst target prices are AMETEK Inc (Symbol: AME), Verisign Inc (Symbol: VRSN), and Trimble Inc (Symbol: TRMB). Although AME has traded at a recent price of $144.06/share, the average ...
See more
What is AXS 14?
When will Axsome 14 be released?
After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia.
When will Axsome submit NDA?
The company will file an NDA in the fourth quarter of 2022.
When will the FDA approve AXS 05?
(NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its plan to submit a New Drug Application (NDA) for AXS-14 for the management of fibromyalgia following a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). AXS-14 (esreboxetine) is a novel, oral, potent, and highly selective norepi
When is AXS 05 FDA action date?
2 days ago. "Analysts who follow the company said the development likely means the FDA, which is slated to make a decision on AXS-05 by Aug. 22, will issue a complete response letter, which indicates that the agency won't approve the application in its current form.".
3.4 Analyst's Opinion
Citing investor focus on AXS-05 which has an FDA action date on August 22 in major depressive disorder (MDD), Suneja points to a tepid interest in AXS-12. Meanwhile, William Blair’s Myles Minter thinks that the approval granted for Harmony’s Wakix was the reason behind the FDA decision.
Is Axsome Therapeutics a buy right now?
Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
How has Axsome Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock.
When is Axsome Therapeutics' next earnings date?
Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXSM stock has decreased by 59.9% and is now trading at $29.57. View which stocks have been most impacted by COVID-19.
How can I listen to Axsome Therapeutics' earnings call?
Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022. View our earnings forecast for Axsome Therapeutics.
How were Axsome Therapeutics' earnings last quarter?
Axsome Therapeutics will be holding an earnings conference call on Tuesday, March 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for AXSM?
Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings data on Monday, November, 8th. The company reported ($0.93) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.95) by $0.02. During the same quarter last year, the company posted ($0.58) EPS. View Axsome Therapeutics' earnings history.
What is Axsome Therapeutics?
9 Wall Street analysts have issued twelve-month target prices for Axsome Therapeutics' shares. Their forecasts range from $34.00 to $180.00. On average, they expect Axsome Therapeutics' share price to reach $89.22 in the next twelve months.
Is ZacksTrade a separate company?
New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
Signals & Forecast
ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Is Axsome Therapeutics stock A Buy?
Axsome Therapeutics finds support from accumulated volume at $28.71 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are positive buying more shares than they are selling in Axsome Therapeutics
Axsome Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Axsome Therapeutics
In the last 100 trades there were 3.13 million shares bought and 493.28 thousand shares sold. The last trade was done 95 days ago by Jeffs Roger who bough 3.95 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Release
- Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Axsome Therapeutics.
Cost
- 6 brokerages have issued 12 month target prices for Axsome Therapeutics' shares. Their predictions range from $23.00 to $45.00. On average, they expect Axsome Therapeutics' share price to reach $28.00 in the next year. This suggests a possible upside of 29.9% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.
Ratings
- 6 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Axsome Therapeutics. News headlines about AXSM stock have trended positive recently, InfoTrie reports. InfoTrie identifies …
Funding
- (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.
Ownership
- Axsome Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Alethea Capital Management LLC (3.42%), BlackRock Inc. (1.40%), Laurion Capital Management LP (0.66%), Royce & Associates LP (0.55%), Parametric Portfolio Associates LLC (0.28%) and EAM Global Investors LLC (0.26%). Company insiders that own Axs…
Business
- Axsome Therapeutics has a market capitalization of $718.16 million. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.
Location
- Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.